Biotek-snakken — Juni 2021
-
smukt handlet - respekt
-
Danaher gør sig ikke i biotekvirksomheder (citat fra hjemmeside: " filtration, separation and purification technologies"), så det er helt misforstået - og kommer ikke til at ske. Man kan læse om hvad de foretager sig på deres hjemmeside https://www.danaher.com/our-businesses
-
Orphazyme nedjusterer: FDA afviser Arimoclomol https://www.proinvestor.com/investornyt/676186/orphazyme-nedjusterer-fda-afviser-arimoclomol-ny
-
Orphazyme/Nordnet: Styrtdyk i sigte efter nådestød fra FDA https://www.proinvestor.com/investornyt/676188/orphazyme-nordnet-styrtdyk-i-sigte-efter-nadestod-fra-fda
-
Ærgerligt og surt for alle Orphazyme aktionærer at det kiksede med Arimoclomol-godkendelsen hos FDA, men især for alle som stadig lider af Niemann-Pick syndromet.
Niemann-Picks sygdom type C - information til sundhedsfaglige - Medicin.dk
Niemann-Picks sygdom type C er en arvelig autosomal recessiv sygdom forårsaget af en defekt lysosomal lipid-transport sekundært til patogene varianter i NPC1 og NPC2 generne
(pro.medicin.dk)
-
Aktier/tendens: Let positive tendenser men næppe for Orphazyme https://www.proinvestor.com/investornyt/676191/aktier-tendens-let-positive-
tendenser-men-naeppe-for-orphazyme -
Four Biotech Names To Watch
https://www.proinvestor.com/index.php?p=debat_1&postid=94411 -
Orphazyme -75%
-
Kurs 23,7
-
Trist for aktionærere men langt mere trist for dem der potentielt kunne behandles:(
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind